Pink Sheet“Pipeline in a pill”-style drug development will be on display in April, when more than half of the user fee goal dates are for new indications on sometimes sprawling labels, as well as one novel biol
ScripIt has been a tough month for Genmab, with Johnson & Johnson opting out of a pact and a lawsuit landing from AbbVie, but the Danish biotech has come out fighting with the announcement of a new sha
In VivoIt’s a big year for Regenxbio. The company has a potential commercial launch of its gene therapy program for MPS II (Hunter syndrome), a Biologics License Application for its Duchenne muscular dystrop
ScripThe six biosimilars to Johnson & Johnson ’s Stelara that have launched in the US have list prices 80% to 90% below the innovator’s wholesale acquisition cost, representing deeper discounts than t